Paragon Capital Management (Kansas)’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $920K | Sell |
15,972
-297
| -2% | -$17.1K | 0.43% | 35 |
|
|
2026
Q1 | $987K | Buy |
16,269
+346
| +2% | +$20.2K | 0.49% | 37 |
|
|
2025
Q4 | $859K | Sell |
15,923
-1,543
| -9% | -$74.2K | 0.44% | 35 |
|
|
2025
Q3 | $788K | Sell |
17,466
-1,031
| -6% | -$48.1K | 0.38% | 37 |
|
|
2025
Q2 | $856K | Buy |
18,497
+503
| +3% | +$24.7K | 0.44% | 37 |
|
|
2025
Q1 | $1.1M | Sell |
17,994
-1,247
| -6% | -$72.7K | 0.63% | 27 |
|
|
2024
Q4 | $1.09M | Sell |
19,241
-804
| -4% | -$44.9K | 0.58% | 27 |
|
|
2024
Q3 | $1.04M | Buy |
20,045
+249
| +1% | +$11.7K | 0.54% | 29 |
|
|
2024
Q2 | $822K | Sell |
19,796
-704
| -3% | -$31.5K | 0.44% | 31 |
|
|
2024
Q1 | $1.11M | Buy |
20,500
+222
| +1% | +$11.3K | 0.6% | 29 |
|
|
2023
Q4 | $1.04M | Sell |
20,278
-22,830
| -53% | -$1.2M | 0.59% | 28 |
|
|
2023
Q3 | $2.5M | Sell |
43,108
-337
| -0.8% | -$20.6K | 1.47% | 19 |
|
|
2023
Q2 | $2.78M | Sell |
43,445
-553
| -1% | -$37.1K | 1.59% | 17 |
|
|
2023
Q1 | $3.05M | Sell |
43,998
-856
| -2% | -$60.4K | 1.85% | 17 |
|
|
2022
Q4 | $3.23M | Sell |
44,854
-186
| -0.4% | -$14K | 2.01% | 17 |
|
|
2022
Q3 | $3.2M | Sell |
45,040
-1,289
| -3% | -$93.5K | 2.07% | 17 |
|
|
2022
Q2 | $3.57M | Buy |
46,329
+717
| +2% | +$54.6K | 2.11% | 17 |
|
|
2022
Q1 | $3.33M | Buy |
45,612
+644
| +1% | +$43.2K | 1.7% | 17 |
|
|
2021
Q4 | $2.8M | Sell |
44,968
-1,391
| -3% | -$81.6K | 1.41% | 19 |
|
|
2021
Q3 | $2.74M | Sell |
46,359
-1,984
| -4% | -$131K | 1.44% | 20 |
|
|
2021
Q2 | $3.23M | Sell |
48,343
-653
| -1% | -$42.6K | 1.61% | 20 |
|
|
2021
Q1 | $3.23M | Sell |
48,996
-2,486
| -5% | -$155K | 1.62% | 20 |
|
|
2020
Q4 | $3.19M | Buy |
51,482
+45,575
| +772% | +$2.8M | 1.72% | 18 |
|
|
2020
Q3 | $356K | Hold |
5,907
| – | – | 0.2% | 36 |
|
|
2020
Q2 | $347K | Buy |
5,907
+515
| +10% | +$30.8K | 0.22% | 33 |
|
|
2020
Q1 | $301K | Buy |
5,392
+71
| +1% | +$4.34K | 0.22% | 32 |
|
|
2019
Q4 | $342K | Hold |
5,321
| – | – | 0.18% | 40 |
|
|
2019
Q3 | $270K | Hold |
5,321
| – | – | 0.14% | 43 |
|
|
2019
Q2 | $241K | Hold |
5,321
| – | – | 0.11% | 50 |
|
|
2019
Q1 | $254K | Buy |
+5,321
| New | +$265K | 0.12% | 48 |
|
|
2018
Q3 | – | Sell |
-3,984
| Closed | -$220K | – | 55 |
|
|
2018
Q2 | $220K | Sell |
3,984
-277
| -7% | -$15K | 0.07% | 63 |
|
|
2018
Q1 | $269K | Buy |
4,261
+252
| +6% | +$16.2K | 0.1% | 57 |
|
|
2017
Q4 | $245K | Hold |
4,009
| – | – | 0.08% | 60 |
|
|
2017
Q3 | $255K | Sell |
4,009
-800
| -17% | -$46.7K | 0.09% | 51 |
|
|
2017
Q2 | $267K | Sell |
4,809
-306
| -6% | -$16.7K | 0.09% | 51 |
|
|
2017
Q1 | $278K | Sell |
5,115
-134
| -3% | -$7.35K | 0.09% | 51 |
|
|
2016
Q4 | $306K | Buy |
5,249
+810
| +18% | +$44.3K | 0.1% | 48 |
|
|
2016
Q3 | $239K | Buy |
4,439
+97
| +2% | +$6.23K | 0.08% | 54 |
|
|
2016
Q2 | $319K | Sell |
4,342
-150
| -3% | -$10.6K | 0.11% | 49 |
|
|
2016
Q1 | $286K | Hold |
4,492
| – | – | 0.11% | 46 |
|
|
2015
Q4 | $309K | Sell |
4,492
-954
| -18% | -$63K | 0.12% | 46 |
|
|
2015
Q3 | $322K | Sell |
5,446
-90
| -2% | -$5.71K | 0.13% | 49 |
|
|
2015
Q2 | $368K | Sell |
5,536
-115
| -2% | -$7.58K | 0.13% | 46 |
|
|
2015
Q1 | $364K | Buy |
5,651
+100
| +2% | +$6.26K | 0.14% | 43 |
|
|
2014
Q4 | $327K | Hold |
5,551
| – | – | 0.12% | 50 |
|
|
2014
Q3 | $284K | Buy |
5,551
+800
| +17% | +$40K | 0.11% | 52 |
|
|
2014
Q2 | $230K | Hold |
4,751
| – | – | 0.09% | 60 |
|
|
2014
Q1 | $246K | Hold |
4,751
| – | – | 0.11% | 61 |
|
|
2013
Q4 | $252K | Hold |
4,751
| – | – | 0.12% | 57 |
|
|
2013
Q3 | $219K | Hold |
4,751
| – | – | 0.11% | 60 |
|
|
2013
Q2 | $212 | Buy |
+4,751
| New | +$206K | 0.11% | 63 |
|
Other funds holding BMY
Paragon Capital Management (Kansas)'s BMY Position: Q2 2026 in Review
Paragon Capital Management (Kansas) reduced its Bristol-Myers Squibb (BMY) stake by 1.8% in Q2 2026, selling an estimated $17.1K and leaving 15,972 shares worth $920K. The position accounts for 0.43% of the portfolio, ranked #35.
Paragon Capital Management (Kansas) first reported a position in BMY in Q2 2013 and has held it in 51 quarters since. The position peaked at $3.57M in Q2 2022. 2,505 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- Paragon Capital Management (Kansas) held 15,972 shares of Bristol-Myers Squibb worth $920K as of Q2 2026.
- Paragon Capital Management (Kansas) sold 297 Bristol-Myers Squibb shares in Q2 2026, an estimated $17.1K.
- Bristol-Myers Squibb made up 0.43% of Paragon Capital Management (Kansas)'s portfolio in Q2 2026, its #35 holding.
- Paragon Capital Management (Kansas) first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 51 quarters since.
- Paragon Capital Management (Kansas)'s Bristol-Myers Squibb position peaked at $3.57M in Q2 2022.
- 2,505 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on Paragon Capital Management (Kansas)'s 13F filing for Q2 2026, filed 5 Aug 2026.